Cooperative Agreement U01CA293883
Award Date
9/18/24
Completion Date
8/31/29
Dollars Obligated
$737K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Honolulu, HI 96813, USA
Similar Awards
The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $398,398 Cooperative Agreement to Cold Spring Harbor Laboratory (CSHL) to discover natural products and natural product derivatives as inhibitors of KLK6 to prevent the progression of preneoplastic ductal pancreatic cancer. The 3-year award, starting July 2025, aims to: 1) perform pseudo-evolution of natural product libraries using SuFEx click chemistry to enhance efficacy and...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $585,458 to Baylor College of Medicine to further validate and refine a mass spectrometry-based proteomic assay for early detection of pancreatic ductal adenocarcinoma (PDAC). The project aims to: 1) determine the performance characteristics and robustness of the assay for clinical utilization; 2) refine the assay's accuracy and thresholds for PDAC detection...
This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...
The National Cancer Institute (NCI) awarded a $616,495 Project Grant under CFDA 93.396 - Cancer Biology Research to The University of Texas MD Anderson Cancer Center. The grant supports research to define the biological role of sulfatide in the development and progression of pancreatic cancer precursor lesions, test whether inhibition of sulfatide metabolism is a viable cancer interception strategy, and conduct a proof-of-concept study using mass spectrometry imaging to identify positive margins...
This $1,130,538 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC) using a newly developed anti-Tn (AREMAB6) monoclonal antibody. The key objectives are to: 1) determine how the Tn antigen enhances PDAC progression and identify Tn-expressing glycoproteins; 2) validate the role of natural killer cells in AREMAB6-mediated...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Federal Grant Program "Cancer Biology Research" (CFDA 93.396), provides $640,760 to The Leland Stanford Junior University to conduct comprehensive research on the fundamental biological mechanisms underlying pancreatic ductal adenocarcinoma (PDAC) metastasis, organ tropism, and immune evasion. The key products and services to be delivered through this 5-year project include: 1) employing molecular...
This $471,675 project grant from the Department of Health and Human Services National Institutes of Health National Cancer Institute Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund research at Oregon Health & Science University to develop a nanoparticle-based blood test to distinguish pancreatic cancer from benign pancreatic disease. The researchers will use high conductance dielectrophoresis technology to simultaneously recover different types of cancer-derived...
The federal Project Grant award R01CA299421, totaling $653,819.00, was awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Johns Hopkins University. The goal of this 5-year project (Feb 2025 - Jan 2030) is to develop a highly specific blood-based early detection test for pancreatic cancer, coupled with innovative approaches to leverage imaging, risk factor, and genetic data to more precisely guide the management of high-risk patients. The...
This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $257,709 to the University of California, Los Angeles (UCLA) to investigate the impact of dietary lipids on the initiation and progression of pancreatic ductal adenocarcinoma (PDA). The research project has two main aims: 1) Examine the effects of a high-fat diet comprised of lard (HFLD), which contains mostly saturated long-chain fatty acids, on PDA tumorigenesis using...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...